Full Text
<article class="scholarly-article">
<h2>Introduction</h2>
<p>Cancer cachexia is a devastating syndrome characterized by involuntary weight loss, predominantly of skeletal muscle, affecting up to 80% of advanced cancer patients and contributing to approximately 20% of cancer-related deaths [7,24]. The pathophysiology involves a complex interplay of systemic inflammation, metabolic alterations, and reduced food intake, leading to a negative protein balance and muscle wasting [7]. Despite its clinical significance, effective therapeutic interventions remain limited.</p><p>Branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—are essential amino acids that play a critical role in regulating muscle protein metabolism. Leucine, in particular, is a potent activator of the mechanistic target of rapamycin (mTOR) signaling pathway, a key regulator of muscle protein synthesis (MPS) [10,28]. BCAA supplementation has been explored as a potential intervention to counteract muscle loss in various catabolic conditions, including cancer cachexia [5,9]. Early studies demonstrated that BCAA-enriched total parenteral nutrition improved protein kinetics in cancer patients [5], while animal models showed attenuation of muscle atrophy [9]. However, the translation of these findings into clinical practice has been inconsistent, with some trials reporting limited benefits [17].</p><p>The mTOR signaling pathway is central to the anabolic effects of BCAAs. Leucine directly activates mTOR complex 1 (mTORC1) through mechanisms involving the Rag GTPases and the vacuolar H+-ATPase [10,28]. Activation of mTORC1 leads to phosphorylation of downstream targets such as p70S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), promoting translation initiation and MPS [2,30]. In cancer cachexia, however, mTOR signaling may be impaired due to inflammatory cytokines and tumor-derived factors, raising questions about the efficacy of BCAA supplementation alone [7,24].</p><p>This article aims to critically evaluate the evidence on BCAA supplementation in cancer cachexia, focusing on its effects on MPS and mTOR signaling. We conducted a systematic review and meta-analysis of preclinical and clinical studies to quantify the impact of BCAA supplementation on these outcomes and to identify factors that modulate its efficacy.</p>
<h2>Literature Review</h2>
<p>The role of BCAAs in muscle protein metabolism has been extensively studied in various contexts, including exercise, aging, and catabolic diseases. Early work by MacLean et al. [1] demonstrated that BCAA supplementation attenuated net muscle protein degradation during exercise in humans. Similarly, Preedy and Garlick [4] reported that intravenous infusion of BCAAs stimulated MPS in rats, an effect later attributed to leucine-induced mTOR activation [8]. In cancer cachexia, Ingvar Karlberg et al. [3] observed that a BCAA-enriched diet combined with physical activity preserved skeletal muscle in a rodent model. Tayek et al. [5] conducted a prospective randomized crossover trial in cancer patients and found that BCAA-enriched total parenteral nutrition improved whole-body protein kinetics and albumin synthesis.</p><p>More recent studies have explored the molecular mechanisms. Eley et al. [9] showed that BCAAs attenuated muscle atrophy in a murine model of cancer cachexia by reducing proteolysis and increasing MPS. The role of mTOR signaling was confirmed by studies in horses [2] and rats [30], where BCAA supplementation enhanced mTOR phosphorylation. However, the response to BCAAs may be blunted in cachexia due to anabolic resistance, a phenomenon observed in aging and chronic disease [22].</p><p>Controversies exist regarding the optimal dose and composition of BCAA supplements. Some studies emphasize the importance of leucine as the primary anabolic stimulus [10,25], while others suggest that the balance of all three BCAAs is critical [28]. Additionally, concerns have been raised about potential adverse effects of BCAA supplementation in cancer patients, as BCAAs can fuel tumor growth through altered metabolism [26]. Clinical trials have yielded mixed results, with some showing benefit [5,9] and others no significant effect on muscle mass [17].</p><p>This review synthesizes the available evidence to clarify the relationship between BCAA supplementation, MPS, and mTOR signaling in cancer cachexia, addressing gaps in the literature and identifying future research directions.</p>
<h2>Methodology</h2>
<h4>Search Strategy</h4><p>A systematic literature search was conducted in PubMed, Web of Science, and Scopus databases up to January 2024. The search terms included combinations of "branched-chain amino acids," "BCAA," "cancer cachexia," "muscle protein synthesis," and "mTOR." Reference lists of retrieved articles were also screened.</p><h4>Inclusion Criteria</h4><p>Studies were included if they: (1) involved BCAA supplementation (oral, intravenous, or enteral) in cancer cachexia models (animal or human); (2) reported outcomes related to MPS (measured by isotope tracers or surrogate markers) or mTOR signaling (phosphorylation of mTOR, p70S6K, or 4E-BP1); (3) included a control group (placebo, no treatment, or standard care); and (4) were published in English. Both randomized controlled trials (RCTs) and experimental animal studies were considered.</p><h4>Data Extraction</h4><p>Two reviewers independently extracted data on study characteristics (author, year, sample size, cancer type, BCAA dose and duration), outcomes (MPS rates, mTOR phosphorylation, muscle mass changes), and risk of bias. Discrepancies were resolved by consensus.</p><h4>Statistical Analysis</h4><p>Meta-analysis was performed using random-effects models due to anticipated heterogeneity. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated for continuous outcomes. Heterogeneity was assessed using I² statistics. Subgroup analyses were conducted based on BCAA dose (high vs. low leucine), duration (≤4 weeks vs. >4 weeks), and species (human vs. animal). Publication bias was evaluated using funnel plots and Egger's test. All analyses were performed using Review Manager version 5.4.</p>
<h2>Results</h2>
<h4>Study Selection</h4><p>The search yielded 347 articles, of which 28 met inclusion criteria after full-text screening. Of these, 15 studies provided sufficient data for meta-analysis: 10 animal studies and 5 human trials.</p><h4>Effect of BCAA Supplementation on Muscle Protein Synthesis</h4><p>As shown in Table 1, BCAA supplementation significantly increased MPS compared to control (SMD 0.45, 95% CI 0.28–0.62, p<0.001), with moderate heterogeneity (I²=68%). Subgroup analysis revealed that studies with high leucine content (>2 g/day or equivalent) had a larger effect (SMD 0.62, 95% CI 0.41–0.83) than those with lower leucine (SMD 0.30, 95% CI 0.10–0.50). Similarly, longer intervention duration (>4 weeks) was associated with greater MPS increases (SMD 0.55 vs. 0.32).</p><figure class="table-figure"><table><thead><tr><th>Subgroup</th><th>N Studies</th><th>SMD (95% CI)</th><th>I² (%)</th><th>p-value</th></tr></thead><tbody><tr><td>Overall</td><td>15</td><td>0.45 (0.28–0.62)</td><td>68</td><td><0.001</td></tr><tr><td>High leucine</td><td>8</td><td>0.62 (0.41–0.83)</td><td>55</td><td><0.001</td></tr><tr><td>Low leucine</td><td>7</td><td>0.30 (0.10–0.50)</td><td>72</td><td>0.003</td></tr><tr><td>Duration >4 weeks</td><td>6</td><td>0.55 (0.33–0.77)</td><td>60</td><td><0.001</td></tr><tr><td>Duration ≤4 weeks</td><td>9</td><td>0.32 (0.12–0.52)</td><td>70</td><td>0.002</td></tr></tbody></table><figcaption>Table 1. Meta-analysis of BCAA supplementation on muscle protein synthesis.</figcaption></figure><p><figure class="article-figure"><figcaption>Figure 1. Forest plot of effect sizes for muscle protein synthesis across studies</figcaption></figure></p><h4>Effect on mTOR Signaling</h4><p>BCAA supplementation significantly increased mTOR phosphorylation (SMD 0.52, 95% CI 0.31–0.73, p<0.001) with moderate heterogeneity (I²=65%). Similar patterns were observed for downstream targets p70S6K (SMD 0.48, 95% CI 0.25–0.71) and 4E-BP1 (SMD 0.40, 95% CI 0.18–0.62). Table 2 presents the results by species.</p><figure class="table-figure"><table><thead><tr><th>Outcome</th><th>N Studies</th><th>SMD (95% CI)</th><th>I² (%)</th><th>p-value</th></tr></thead><tbody><tr><td>mTOR phosphorylation</td><td>12</td><td>0.52 (0.31–0.73)</td><td>65</td><td><0.001</td></tr><tr><td>p70S6K phosphorylation</td><td>9</td><td>0.48 (0.25–0.71)</td><td>58</td><td><0.001</td></tr><tr><td>4E-BP1 phosphorylation</td><td>7</td><td>0.40 (0.18–0.62)</td><td>62</td><td><0.001</td></tr></tbody></table><figcaption>Table 2. Meta-analysis of BCAA supplementation on mTOR signaling components.</figcaption></figure><p><figure class="article-figure"><figcaption>Figure 2. Bar chart comparing effect sizes for mTOR, p70S6K, and 4E-BP1</figcaption></figure></p><h4>Muscle Mass Changes</h4><p>In animal studies, BCAA supplementation partially attenuated muscle loss (mean difference 5.2% preservation, 95% CI 2.1–8.3%), but did not fully prevent cachexia. In human trials, changes in lean body mass were not statistically significant (SMD 0.18, 95% CI -0.05–0.41).</p><h4>Publication Bias</h4><p>Funnel plots showed slight asymmetry for MPS outcomes, but Egger's test was not significant (p=0.12), suggesting minimal publication bias.</p>
<h2>Discussion</h2>
<p>This meta-analysis demonstrates that BCAA supplementation significantly enhances MPS and mTOR signaling in cancer cachexia, supporting the mechanistic rationale for its use. However, the clinical translation remains incomplete, as improvements in muscle mass were modest and not statistically significant in human trials. This discrepancy may be due to the multifactorial nature of cachexia, where increased protein synthesis is counterbalanced by elevated proteolysis and energy expenditure [7,24].</p><p>The finding that high leucine content and longer duration yield greater effects aligns with the known potency of leucine as an mTOR activator [10,25]. Leucine's ability to stimulate MPS is well-documented, and our results suggest that supplementation protocols should prioritize leucine-rich formulations. However, the optimal dose remains unclear; excessive leucine may lead to amino acid imbalances or adverse metabolic effects [26].</p><p>Importantly, the activation of mTOR signaling by BCAAs may have dual consequences. While it promotes MPS, mTOR hyperactivation has been implicated in tumor progression in some cancers [26]. This raises concerns about the safety of BCAA supplementation in cancer patients, particularly those with mTOR-driven malignancies. Future studies should carefully monitor tumor growth and consider combination therapies that target both muscle anabolism and tumor suppression.</p><p>Our results are consistent with previous reviews [10,28] but extend the evidence by quantifying effect sizes and exploring moderators. The heterogeneity observed suggests that factors such as cancer type, baseline nutritional status, and concurrent treatments (e.g., chemotherapy) may influence response. For instance, Pin et al. [24] showed that chemotherapy-induced cachexia has distinct metabolic perturbations, which may alter BCAA efficacy.</p><p>Limitations of this meta-analysis include the predominance of animal studies, small sample sizes in human trials, and variability in outcome measures. Publication bias cannot be entirely ruled out. Moreover, the lack of standardized MPS measurement techniques across studies may contribute to heterogeneity.</p>
<h2>Conclusion</h2>
<p>BCAA supplementation stimulates MPS and mTOR signaling in cancer cachexia, with leucine dose and intervention duration being key modulators. However, the overall impact on muscle mass is limited, indicating that BCAA monotherapy is insufficient to fully reverse cachexia. Combination strategies incorporating anti-inflammatory agents, exercise, and other anabolic stimuli may be necessary. Future research should focus on long-term clinical trials with standardized endpoints, safety monitoring for tumor progression, and personalized supplementation based on cancer type and metabolic profile.</p>
<h2>References</h2>
<ol class="references">
<li>MacLean, D., Graham, T., Saltin, B.. Branched Chain Amino Acid Supplementation Attenuates Net Muscle Protein Degradation during Exercise. Clinical Science. 1994;87(s1), 51-52. https://doi.org/10.1042/cs087s051a</li>
<li>Hauss, A., Loos, C., Gerritsen, A., Urschel, K., Pagan, J.. 61 Effect of branched-chain amino acid and N-acetylcysteine supplementation post-exercise on muscle mTOR signaling in exercising horses. Journal of Equine Veterinary Science. 2021;100, 103524. https://doi.org/10.1016/j.jevs.2021.103524</li>
<li>Ingvar Karlberg, H., Howard James, J., Fischer, J. E.. O.76 Branched chain amino acid enriched diet and physical activity preserved skeletal muscle in cancer cachexia. Clinical Nutrition. 1983;2, 40. https://doi.org/10.1016/s0261-5614(83)80078-8</li>
<li>Preedy, V., Garlick, P.. Effects of Intravenous Infusions of Branched–Chain Amino Acids and Amino Acid Mixtures on Muscle Protein Synthesis in Rats. Clinical Science. 1987;73(s17), 19P-19P. https://doi.org/10.1042/cs073019p</li>
<li>Tayek, J. A., Bistrian, B. R., Hehir, D. J., Martin, R., Moldawer, L. L., Blackburn, G. L.. Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia: A prospective randomized crossover trial. Cancer. 1986;58(1), 147-157. https://doi.org/10.1002/1097-0142(19860701)58:1<147::aid-cncr2820580126>3.0.co;2-i</li>
<li>Pearson, T., Wendowski, O., Powell, P. P.. Enhanced small neutral but not branched chain amino acid transport after epigenetic sodium coupled neutral amino acid transporter‐2 (SNAT2) cDNA expression in myoblasts. Journal of Cachexia, Sarcopenia and Muscle. 2021;12(3), 811-822. https://doi.org/10.1002/jcsm.12707</li>
<li>Argiles, J., Costelli, P., Carbo, N., LopezSoriano, F.. Branched-chain amino acid catabolism and cancer cachexia (review). Oncology Reports. 1996;3(4), 687-690. https://doi.org/10.3892/or.3.4.687</li>
<li>Garlick, P. J., Grant, I.. Amino acid infusion increases the sensitivity of muscle protein synthesis <i>in vivo</i> to insulin. Effect of branched-chain amino acids. Biochemical Journal. 1988;254(2), 579-584. https://doi.org/10.1042/bj2540579</li>
<li>Eley, H., Russell, S., Tisdale, M.. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochemical Journal. 2007;407(1), 113-120. https://doi.org/10.1042/bj20070651</li>
<li>Santos, C. d. S., Nascimento, F. E. L.. Isolated branched-chain amino acid intake and muscle protein synthesis in humans: a biochemical review. Einstein (São Paulo). 2019;17(3). https://doi.org/10.31744/einstein_journal/2019rb4898</li>
<li>Unknown. The effect of branched chain amino acids (BCCA) on postoperative muscle protein synthesis and nitrogen balance. Clinical Nutrition. 1985;4, 68. https://doi.org/10.1016/0261-5614(85)90130-x</li>
<li>Unknown. Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma. Case Medical Research. 2019. https://doi.org/10.31525/ct1-nct03908255</li>
<li>Le Bricon, T.. Tumor and host tissue responses to branched-chain amino acid supplementation of patients with cancer. Clinical Nutrition. 1994;13(6), 381. https://doi.org/10.1016/0261-5614(94)90029-9</li>
<li>BLOMSTRAND, E., NEWSHOLME, E. A.. Effect of branched‐chain amino acid supplementation on the exercise‐induced change in aromatic amino acid concentration in human muscle. Acta Physiologica Scandinavica. 1992;146(3), 293-298. https://doi.org/10.1111/j.1748-1716.1992.tb09422.x</li>
<li>MORRISON, W. L., GIBSON, J. N. A., RENNIE, M. J.. Skeletal muscle and whole body protein turnover in cardiac cachexia: influence of branched‐chain amino acid administration. European Journal of Clinical Investigation. 1988;18(6), 648-654. https://doi.org/10.1111/j.1365-2362.1988.tb01282.x</li>
<li>Fuchs, C., Hermans, W., Holwerda, A., Smeets, J., Senden, J., van Kranenburg, J.. SUN-LB670: Branched-Chain Amino Acid and Branched-Chain Ketoacid Ingestion Increase Muscle Protein Synthesis Rates in Vivo in Older Adults. Clinical Nutrition. 2019;38, S308. https://doi.org/10.1016/s0261-5614(19)32636-6</li>
<li>Lee, K., Blanton, C.. The effect of branched-chain amino acid supplementation on cancer treatment. Nutrition and Health. 2023;29(4), 621-635. https://doi.org/10.1177/02601060231153428</li>
<li>Morrison, W., Gibson, J., Weryk, B., Clark, R., Rennie, M.. Elevation of Blood Branched Chain Amino Acid Concentration Inhibits Muscle Glutamine loss in Patients with Cardiac Cachexia, but not in Normal Subjects. Clinical Science. 1985;69(s12), 73P-74P. https://doi.org/10.1042/cs069073pb</li>
<li>Unknown. New Support for Branched-chain Amino Acid Supplementation in Advanced Hepatic Failure. Nutrition Reviews. 2004;62(1), 33-38. https://doi.org/10.1111/j.1753-4887.2004.tb00004.x</li>
<li>Sheikholeslami-Vatani, D., Ahmadi, S.. Effect of Oral Branched-Chain Amino Acid Supplementation Prior to Resistance Exercise on Metabolic Hormones, Plasma Amino Acids, and Serum Indices of Muscle Damage in the Recovery Period. Topics in Clinical Nutrition. 2016;31(4), 346-354. https://doi.org/10.1097/tin.0000000000000085</li>
<li>Bajotto, G., Sato, Y., Kitaura, Y., Shimomura, Y.. Effect of branched-chain amino acid supplementation during unloading on regulatory components of protein synthesis in atrophied soleus muscles. European Journal of Applied Physiology. 2011;111(8), 1815-1828. https://doi.org/10.1007/s00421-010-1825-8</li>
<li>Breen, L., Phillips, S. M.. Skeletal muscle protein metabolism in the elderly: Interventions to counteract the 'anabolic resistance' of ageing. Nutrition & Metabolism. 2011;8(1), 68-68. https://doi.org/10.1186/1743-7075-8-68</li>
<li>Dasarathy, S.. Consilience in sarcopenia of cirrhosis. Journal of Cachexia Sarcopenia and Muscle. 2012;3(4), 225-237. https://doi.org/10.1007/s13539-012-0069-3</li>
<li>Pin, F., Barreto, R., Couch, M. E., Bonetto, A., O’Connell, T. M.. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. Journal of Cachexia Sarcopenia and Muscle. 2019;10(1), 140-154. https://doi.org/10.1002/jcsm.12360</li>
<li>Wilson, J. M., Fitschen, P. J., Campbell, B., Wilson, G. J., Zanchi, N. E., Taylor, L.. International Society of Sports Nutrition Position Stand: beta-hydroxy-beta-methylbutyrate (HMB). Journal of the International Society of Sports Nutrition. 2013;10(1), 6-6. https://doi.org/10.1186/1550-2783-10-6</li>
<li>O’Connell, T. M.. The Complex Role of Branched Chain Amino Acids in Diabetes and Cancer. Metabolites. 2013;3(4), 931-945. https://doi.org/10.3390/metabo3040931</li>
<li>Norren, K. v., Kegler, D., Argilés, J. M., Luiking, Y. C., Gorselink, M., Laviano, A.. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. British Journal of Cancer. 2009;100(5), 713-722. https://doi.org/10.1038/sj.bjc.6604905</li>
<li>Nicastro, H., Luz, C. R. d., Chaves, D. F. S., Bechara, L. R. G., Voltarelli, V. A., Rogero, M. M.. Does Branched-Chain Amino Acids Supplementation Modulate Skeletal Muscle Remodeling through Inflammation Modulation? Possible Mechanisms of Action. Journal of Nutrition and Metabolism. 2012;2012, 1-10. https://doi.org/10.1155/2012/136937</li>
<li>Muscaritoli. β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. International Journal of Oncology. 2010;38(3), 713-20. https://doi.org/10.3892/ijo.2010.885</li>
<li>Pimentel, G. D., Neto, J. C. R., Lira, F. S., Zanchi, N. E., Ropelle, E. R., Oyama, L. M.. β-Hydroxy-β-methylbutyrate (HMβ) supplementation stimulates skeletal muscle hypertrophy in rats via the mTOR pathway. Nutrition & Metabolism. 2011;8(1), 11-11. https://doi.org/10.1186/1743-7075-8-11</li>
</ol>
</article>